Angiogenesis and cancer: recent advances.
Recent studies have shown the possibility to treat cancer with drugs that affect the formation of new blood vessels instead of attacking directly the malignant cell. This relatively new field in the area of oncology on angiogenesis inhibition has expanded the therapeutic option for malignant diseases. We will discuss several antiangiogenesis drugs in clinical development and their mechanism of action. Some of these drugs include: angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, interferons and others. The use of antiangiogenic agents, both in combination with other treatment modalities in the acute setting as well as long-term maintenance or prevention of cancer, is at present one of the better promises in the war against cancer.
Cáceres
William
W
San Juan Veterans Affairs Medical Center, 10 Calle Casia, San Juan, Puerto Rico 00921. wcjn@prtc.net
González
Samuel
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins; D002986:Clinical Trials as Topic; D003094:Collagen / Q000627:therapeutic use; D043169:Endostatins; D006801:Humans; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D010446:Peptide Fragments; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen